{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-24-000149","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.233972+00:00","generated_at":"2026-05-31T12:08:07.578859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MacroGenics Q2 net loss $55.7M; receives $100M Incyte milestone","bullets":["Net loss of $55.7M ($0.89 diluted EPS) vs net income of $57.5M in Q2 2023.","Revenue of $10.8M, down from $13.1M YoY, driven by lower Provention revenue.","Cash $140.4M at June 30; $100M Incyte milestone received post-quarter extends cash runway into 2026.","TAMARACK Phase 2 mCRPC data (vobra duo) to be presented at ESMO in September 2024.","MGC028 IND expected by end 2024; LORIKEET Phase 2 enrollment completion anticipated in 2024/early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-24-000149","json":"https://secwatch.observer/filing/0001125345-24-000149.json","markdown":"https://secwatch.observer/filing/0001125345-24-000149.md","text":"https://secwatch.observer/filing/0001125345-24-000149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000149/0001125345-24-000149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000149/mgnx-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:08:07.578859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}